TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04934748
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine will be infused at a rate sufficient to maintain the intraoperative MAP designated in the underlying GUARDIAN trial.
Study: NCT04986865
Drug: ATG-101
Normalized name: ATG-101
DrugBank: ATG-101 (DB17162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
Study: NCT04629508
Drug: itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: itacitinb Immediate Release (IR) will be dosed orally twice a day
Study: NCT05407441
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, twice daily, dosage per protocol
Study: NCT05407441
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV, dosage and schedule per protocol
Study: NCT05407441
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV, dosage and schedule per protocol
Study: NCT06022861
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
Study: NCT04657094
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04768504
Drug: Tofacitinib 10 mg
Normalized name: tofacitinib 10 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib 10 mg PO BID for 30 days
Study: NCT06551324
Drug: PF-06821497
Normalized name: PF-06821497
DrugBank: PF-06821497 (DB14799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 875 mg BID (2 times a day)
Study: NCT06551324
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV (every 21 days)
Study: NCT06551324
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg QD
Study: NCT06047080
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) glofitamab
Study: NCT06047080
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV polatuzumab vedotin in combination with R-CHP
Study: NCT06047080
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV rituximab
Study: NCT04805606
Drug: CKD-843 A
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose
Study: NCT04805606
Drug: CKD-843 B
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose
Study: NCT06047080
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oral prednisone as part of CHP chemotherapy
Study: NCT04824092
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06790095
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) injection, loading dose of 2.5 mg/kg (diluted in 0.9% NaCl to a final volume of 50 ml) given over 2 hours, immediately followed by a continuous IV infusion of of 5 mg/kg/day (diluted in 0.9% NaCl to a final volume of 250 ml) for 3 days (72-hour).
Study: NCT04824092
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Tafasitamab placebo
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT04824092
Drug: Lenalidomide placebo
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study: NCT06625489
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib will be administered.
Study: NCT05622864
Drug: HRS-9821
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-9821
Study: NCT04741880
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.
Study: NCT04741880
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.
Study: NCT00000740
Drug: Sitamaquine
Normalized name: Sitamaquine
DrugBank: Sitamaquine (DB04909)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04865380
Drug: Tranexamic Acid 100 MG/ML
Normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g IV x 1 dose of Tranexamic Acid administered preoperatively.
Study: NCT04328714
Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.
Study: NCT06622226
Drug: ONO-7018
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7018 tablet(s) are administered orally.
Study: NCT05889182
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablets
Study: NCT06784180
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mcg intrathecal morphine
Study: NCT06784180
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)
Study: NCT06784180
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mcg intrathecal hydromorphone
Study: NCT06790394
Drug: Florbetaben F18
Normalized name: florbetaben F18
DrugBank: Florbetaben F-18 (DB09148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
Study: NCT06609239
Drug: Lunsekimig
Normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection
Study: NCT06348927
Drug: sunvozertinib in combination with Anlotinib
Normalized name: miconazole
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
Study: NCT05848739
Drug: ST316
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV
Study: NCT05848739
Drug: FOLFIRI regimen & bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg.
Study: NCT05848739
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg once a day for the first 21 days of a 28-day cycle
Study: NCT04500626
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy delivered in a monoplace or multi-place chamber. Supervised by a hyperbaric oxygen therapy physician and a chamber operator.
Study: NCT05848739
Drug: Lonsurf & bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
Study: NCT04997317
Drug: 177Lu-DOTA-JR11 (Phase I/II)
Normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the phase I/II part of the study: 3 cycles of 177Lu-DOTA-JR11 will be administered with an activity of 4.5-7.4 GBq. Two additional 177Lu-DOTA-JR11 treatment cycles can be performed if clinically indicated
Study: NCT05712460
Drug: sisunatovir
Normalized name: Sisunatovir
DrugBank: Sisunatovir (DB15674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV
Study: NCT05679388
Drug: Relugolix Pill
Normalized name: relugolix Pill
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A medication used to treat prostate cancer. Relugolix comes as a tablet to take by mouth. It is usually taken with or without food once daily.
Study: NCT05679388
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HIV antiviral It can treat HIV infection, which causes AIDS. It does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease and prolong life.
Study: NCT05679388
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A drug used to treat fungal infections.
Study: NCT05675579
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV (vein)
Study: NCT05675579
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT06279000
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine Group:~IMP = Colchicine (0.5 mg, enteral) first application in the evening before day of surgery, following a 1-0-1 regimen until the third postoperative day, ending with the application of the ninth dose. Colchicine tablets are provided as 1 mg tablets with a score, which must be divided before ingestion.
Study: NCT04880980
Drug: Terbinafine Pill
Normalized name: terbinafine Pill
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.
Study: NCT04880980
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
Study: NCT06791031
Drug: inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group.
Study: NCT02955446
Drug: PF-03084014
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
Study: NCT05672667
Drug: intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin given by intravenous route
Study: NCT05672667
Drug: intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin given by intranasal administration
Study: NCT06389201
Drug: HCQ
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCQ, 400-600mg, oral tablet, once, one day before chemotherapy and radiotherapy. During therapy, HCQ maintenance dose is 200-400mg daily.
Study: NCT06784557
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High intensity HMG-CoA reductase inhibitor
Study: NCT06784557
Drug: Atorvastatin 20mg+Ezetimibe 10mg
Normalized name: atorvastatin / ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
Study: NCT04938882
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT06754501
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein
Study: NCT06754501
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by vein
Study: NCT04938882
Drug: Compound lidocaine at low concentration
Normalized name: rose bengal AT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT04938882
Drug: Compound lidocaine at high concentration
Normalized name: rose bengal AT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the induction of anesthesia, 0.6% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT06529536
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus is administered to all patients post SOT at RCH
Study: NCT05280496
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
Study: NCT05138653
Drug: CVL-354
Normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution/suspension
Study: NCT05138653
Drug: CVL-354
Normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05093270
Drug: BGB-23339
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a tablet
Study: NCT05904886
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study: NCT05904886
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study: NCT05904886
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.
Study: NCT05804708
Drug: GH001
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH001 is administered via inhalation
Study: NCT05954312
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05954312
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT05296512
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
Study: NCT05296512
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib.
Study: NCT05946564
Drug: Pioglitazone (ACTOS®)
Normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be randomize in the intervention group receive treatment by pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.
Study: NCT05946564
Drug: Placebo of Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be randomize in the intervention group receive treatment by placebo of pioglitazone (30 mg/day orally) for 26 weeks on top of a SOC immunosuppressive treatment.